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ABSTRACT
An assay has been developed (restriction endo-
nuclease digestion assay - RED100) based on inhibition
of the restriction endonuclease BamHl that Is capable
of quantitative evaluation of the relative DNA-binding
affinity of pyrrolo[2,1-c][1 ,4]benzodiazepine (PBD)
antitumour antibiotics. This method provides com-
parable results to those obtained from thermal
denaturation and ethidium bromide displacement
assays but is much more sensitive, discriminating
between molecules of similar structure such as DC-81,
iso-DC-81 and neothramycin. The results reveal a trend
between relative DNA-binding affinity and in vitro
cytotoxicity for the PBDs in two tumour cell lines
studied.
INTRODUCTION
The pyrrolo[2, 1-c][ 1 ,4]benzodiazepines (PBDs, Figure 1) are a
family of sequence-selective DNA-binding antitumour antibiotics
that bind exclusively to the exocyclic N2 of guanine in the minor
groove of DNA (Figure 2) (1-2). These molecules possess an
(S)-configuration at the chiral C1 la-position which provides them
with a right-handed twist when viewed from the A-ring towards
the C-ring. This feature provides the appropriate three-
dimensional shape for isohelicity with the minor groove of B-
form DNA, leading to a snug fit at the binding site. Well known
members of the PBD family include anthramycin, tomaymycin,
DC-81, neothramycin and sibiromycin. Footprinting-type studies
have shown that the adducts span 3 base-pairs with a rank order
of preference for 5'-Pu-G-Pu > 5'-Pu-G-Py or 5'-Py-G-Pu >
5'-Py-G-Py sequences (2-4). Recent high-field NMR and
molecular modelling studies have provided detailed information
about the precise three-dimensional structure of some PBD-
adducts, including orientation of the molecule in the groove and
stereochemistry at the Cl 1-position (2). So far, there is little
understanding of the relationship between DNA-binding affinity,
sequence-selectivity, and either in vitro cytotoxicity or in vivo
antitumour activity. This is due, in part, to the lack of a sensitive
and biologically relevant assay to compare the binding affinities
of known PBDs. Although thermal denaturation (5) and ethidium
bromide displacement (6) assays (ATm and EB60, respectively)
have been useful in providing data, they are not sensitive enough
to discriminate between weakly binding compounds of similar
structure witiin this family.
The principle of inhibiting a restriction endonuclease by DNA-
interacting ligands as a means to evaluate relative DNA-binding
affinity has been investigated by a number of groups; for example
cis-platin (7) and peptide nucleic acid chimeras (8) have been
studied. Inhibition of restriction endonucleases by a PBD was
originally established by Sumner and Bennet (9), who
demonstrated significant inhibition with anthramycin. However,
the relationship between the concentration of anthramycin and
the degree of inhibition was not investigated, and it was not clear
from the study whether the effect was unique to anthramycin or
was a general effect with other members of the PBD family. In
this study, several members of the PBD family of various
structure have been investigated for their ability to inhibit
endonuclease cleavage activity, and a concentration dependence
has been established for the inhibition.
MATERIALS AND METHODS
Anthramycin and tomaymycin methyl ethers, neothramycins A
and B (3-0-butyl ethers) and sibiromycin were gifts from
Hoffimann-La Roche Corporation (New Jersey, USA), Fujisawa
Corporation (Ibaraki, Japan), the Institute of Microbial Chemistry
(Tokyo, Japan), and Kyowa Hakko Kogyo Co. Ltd (Tokyo,
Japan), respectively. DC-81 and iso-DC-81 were synthesised in
this laboratory (10,11).
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Figure 1. Structures of the pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumour
antibiotics evaluated using the RED1OO assay.
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Figue 2. Mechanism of action of the PBDs: Fornation of an aminal bond between
the C11-position of the PBD and N2 of guanine.
Stock solutions of the PBD (1mM) were prepared by dissolving
each compound in the minimmum amount of methanol (Aldrich,
HPLC grade) before making up to volume with sterile water.
All solutions were stored at 4°C. Methanol concentrations greater
than 8%v/v were found to inhibit restriction endonuclease
activity; therefore, this concentration of co-solvent was not
exceeded in final stock solutions.
pBR322 plasmid transformed into E. coli was supplied by
Dr K.Firman (Biophysics Department, University of Portsmouth,
UK). Cells bearing the plasmid were grown, amplified with
ampicillin (20,ug/ml), the DNA isolated by alkaline lysis, and
then purified by treatment with RNase A, phenol extraction,
polyethyleneglycol (PEG) 8000 precipitation and ethanol
precipitation (12). pBR322 DNA samples were stored at -20°C
in Tris-HCI buffer (1OmM Tris-HCl, pH7.8) containing lmM
EDTA.
Restriction endonuclease BamHI supplied with One-Phor-
AlTm (x 10) restriction buffer (OPA+ 100mM Tris-HCl pH
7.5, 1mM EDTA, 100mM magnesium acetate, 500mM
potassium acetate) was purchased from Pharmacia. All other
reagents (molecular biology grade) were purchased from Sigma.
Pu Pu BamHI PuGPu
TCATGGCGACCACACCCGT 0TACGCCGACGCATCGTG303,AGTACCGCTGGTGTGGGCAGGAC CT GATGCGGCCTGCGTAGCAC5'
PuGPu PuGPu
SspI PuGPu
B 5'CTCATACTCTTCCTTTTT T TTGAAGCATTTATCAtAGTTATTG34
3'GAGTATGAGAAGGAAAAA T AACTTCGTAAATAGTCCCAATAAC5'
PuGPu
Figure 3. DNAstar sequence analysis ofpBR322 (A: 350-400 bp, B: 4150-4200
bp) for BamHI (5'-GGATCC) and SspI (5'-AATATT) restriction sites, and PBD
binding sites.
RED100-restriction endonuclease digestion assay
PBD-DNA complexes were prepared by incubating plasmid
DNA (0.5lig) with a range of concentrations of the PBD in
OPA+ (x2) restriction buffer (pH 7.5) and bovine serum
albumin (BSA) (0.1mg/ml) in a reaction volume of 491I for lh
at 37°C. An excess of BamHI (20 units in 1ll) was added and
the restriction digestion carried out by incubation for a further
lh at 37°C in a final volume of 50jid. SspI at concentrations
equivalent to BamHI was also used as a control in some cases.
Each digestion was stopped by incubation for 20 min at 65°C
followed by 10 min at 4°C. 15,ul (lSOng of plasmid DNA) from
each digestion was added to 10,ul of loading buffer (0.25%
bromophenol blue, 40% sucrose) and loaded onto a 1.0%
horizontal agarose gel which was run in Tris-acetate EDTA buffer
(TAE-4OmM Tris base, pH 8.0, 18mM glacial acetic acid, lmM
EDTA) at 100V for 2h. The gels were stained with ethidium
bromide (2,g/ml) for 30 min and then destained for 10 min in
TAE buffer. The DNA bands were visualised by ultraviolet
illumination and photographed (f5.6/60s) using Polaroid 665 (iso
80/20°C) film. Negatives were washed with distilled water and
allowed to dry prior to densitometric analysis. Each lane of a
gel was scanned with a Gelscan XL densitometer and the ratios
between open-circular, linear and supercoiled DNA forms were
determined in order to obtain the percentage of linear DNA
present. The amount of linear DNA was thus considered to be
inversely related to the DNA-binding affmity of the PBD.
Thermal denaturation studies
The PBD compounds were studied in DNA thermal denaturation
experiments using calf thymus (CT) DNA (type-I, highly
polymerized). The CT-DNA had A26JA280 = 1.9, and was
satisfactorily free from protein; a molar extinction value at 260nm
of e = 6600 M-Icm-I was used. Aqueous solutions of DNA
were prepared in Millipore-purified water buffered at pH
7.00-0.01 using 10mM sodium phosphate and lmM EDTA;
no added salt or support electrolyte was used. Working solutions
containing lI0OM of DNA alone and in the presence ofAM of
a PBD compound were monitored at 260nm using a Varian-Cary
219 spectrophotometer fitted with a Neslab ETP-3/RTE4
circulating water heating/cooling accessory. All PBD-DNA
solutions were incubated at 37°C for 18h prior to examination.
Heating was applied at 1 °C min-I from 40°C until thermal
denaturation of the DNA was complete, as judged from the
increase in absorption. The optical absorbance versus temperature
curves were sampled, normalised and analysed as previously
described (5). Thermal denaturation temperatures (Ta,) were
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Table 1.
Compound RED1Wa ATmb EB6c IC50(M)d(jtM) (OC) (mM) L1210 PC6
sibiromycin 1.9 16.3 i 0.1 0.01 0.0029 0.000017
anthramycin 13.3 13.0 X 0.1 0.02 0.022 0.0028
tomaymycin 182.1 2.6 X 0.1 1.00 0.0037 0.0018
DC-81 719.6 0.7 + 0.1 >1.00 0.38 0.33
neothramycin 1208.2 0.8 + 0.1 >1.00 2.7 1.3
iso-DC-81 1526.1 0.6 0.2 nd 2.7 2.7
aConcentration of PBD required to inhibit BamHI cleavage by 100%. bThermal denaturation studies with calf
thymus DNA (ATm for a 5:1 molar ratio of DNAp:PBD following incubation at 370C for 18h). CConcentration
of PBD required to decrease fluorescence due to ethidium bromide DNA-binding to 60% of the PBD-free control
(nd = not determined). dDose of PBD required to inhibit cell growth by 50% compared with PBD-free controls.
Compounds were dissolved in DMSO and then diluted to provide a final concentration of 0.05 v/v% DMSO.
Incubation times (370) were: L1210, 3 days; PC6, 4 days.
determined at a relative absorbance value of 0.50 and are reported
as the mean s.e.m. of at least four determinations. The change
in Tm (AT,,,) following interaction of CT-DNA with an added
PBD was evaluated from:
ATm = Tm(DNA-PBD)-Tm(DNA)
and is reported (Table 1) for a fixed [DNAp]: [PBD] molar ratio
of 5:1. This value was selected following trials to establish the
saturation concentration of each compound, and from experience
with other agents which bind via the minor groove of duplex
DNA (5). The ratio selected did not lead to saturation of DNA
binding.
RESULTS
The principle of the RED0OO assay is based upon the ability of
a PBD to inhibit the cleavage activity of restriction endonuclease
BamHI. Figure 3A shows a partial sequence (350-400 bp) of
pBR322 with the preferred PBD (5'-Pu-G-Pu), BamHI (5'-GG-
ATCC) and SspI (5'-AATATT) binding sites located by the
DNAstar programme (13). The BamHJ cleavage sequence
overlaps with several favoured PBD binding sites suggesting that
ligand-binding has the potential to inhibit BamHI cleavage
activity. The initial objective of this study was to examine a range
of [PBD]:[DNA] molar ratios for the ability to inhibit DNA
linearisation by BamHI. However, equivalent experiments were
carried out with SspI, which cleaves at an AT-rich site that does
not overlap with favourable PBD binding sites (Figure 3B). These
experiments acted as a control to confirm that the measured DNA-
binding affinity was associated with binding of PBDs at the
restriction endonuclease cleavage site.
Figure 4 shows a typical RED0oo assay gel for anthramycin
including two controls: open-circular and supercoiled DNA in
lane 1, and fully linearised DNA in lane 2. As the concentration
ofPBD is increased (lanes 3-10), the total percentage of linear
DNA produced decreases in proportion to PBD concentration.
Laser densitometry was used to quantitate the amount of linear
DNA formed as a percentage of the three forms of DNA.
Extrapolation of a plot of percentage linear DNA formed versus
PBD concentration (Figure 5) allowed the concentration required
to completely inhibit enzyme-induced DNA cleavage (RED1oo)
to be found. One advantage of this quantitation procedure is that
the amount of open-circular form of the DNA at the start of the
assay is not relevant. A second advantage is that using
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Flgure 4. 1% agarose electrophoresis gel showing inhibition ofBamHI cleavage
of pBR322 by antiramycin. Anthramycin-DNA complexes were prepared by
incubating 0.5Sg pBR322 with varying concentrations of anthramycin in a 49p1
reaction volume containing O.1mg/ml BSA and OPA+ buffer (x2) for lh at
37°C. Excess BamHI (20 units in 1l1) was then added to give a final volume
of 50p1 and restriction digestion canied out by incubation for lh at 370C. Digestion
was stopped by heating for 20 min at 65°C followed by cooling for 10 min at
40C. DNA (lSOng) from each digest was loaded onto a 1% agarose gel using
bromophenol blue loading buffer and electrophoresed for 2h at IOOV in TAE
buffer. Lane 1: Control pBR322; lane 2: complete digest of pBR322 by BamHI;
lanes 3-10: anthamycin-pBR322 complexes digested by BamHI with anthramycin
concentrations of 1.8, 3.7, 5.5, 7.3, 9.2, 11.0, 12.8 and 14.6 1M, respectively.
OC = open-circular, L = linear, and SC = supercoiled pBR322.
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Figure 5. Graph representing the effect of PBD concentration on the inhibition
of cleavage of pBR322 by BamHl: sibiromycin (O), anthramycin (E),
tomaymycin (0), DC-81 (0), neothramycin (A), and iso-DC-81 (/). The lines
represent linear regression fits to the data; slope values (and regression coefficients)
are -84.2 (0.99), -28.2 (0.97), -40.9 (0.97), -34.6 (0.94), -35.9 (0.96)
and -39.6 (0.99), respectively. In all cases, PBD concentrations of < O.OlzM
gave no inhibition of BamHI cleavage.
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extrapolated values for 100% inhibition avoids any problems
associated with crossed linear regression plots. The significance
of the slope value for each PBD is not fully understood, although
it is suggested that differences may reflect other competitive
binding modes.
Inhibition experiments for the PBDs (Figure 5) show a clear
rank order of inhibition of cleavage: sibiromycin > anthramycin
> tomaymycin > DC-81 > neothramycin > iso-DC-81 in
terms of RED0oo value. This rank order of inhibition is identical
to that observed for DNA-PBD binding as measured by ATm
and EB60 studies for sibiromycin, anthramycin and tomaymycin
(Table 1). Interestingly, neither of the latter spectrophotometric
methods is able to discriminate between DC-81, iso-DC-81 and
neothramycin, presumably due to the similarity in the ability of
these molecules to stabilize the double-stranded helix, a process
that depends mainly on the strength of hydrogen bonding and
van der Waals interactions between the PBD and DNA bases
in the minor groove. However, DC-81 was shown to have an
approximately 1.5-fold greater REDIoo value compared to
neothramycin, and an approximately two-fold difference between
DC-81 and iso-DC-81 was observed (Table 1). Furthermore, the
PBDs failed to inhibit SspI cleavage at concentrations equivalent
to their REDIoo concentrations for experiments with BamHI.
The data in Table 1 indicate that there is a broad correlation
between the RED100 and in vitro cytotoxicity (IC50) values
determined in L1210 and PC6 cell lines, with sibiromycin and
iso-DC-81 being the most and least cytotoxic compounds,
respectively. This trend is reflected in both the ATm and EB60
data, although it is clear that the RED1oo assay provides superior
resolution of the DNA-modifying abilities of compounds of
different structures.
DISCUSSION
The results (Table 1) show that this assay is capable of
determining the rank order of DNA-binding affinity for a series
of PBD molecules. Although the measurement step relates to
inhibition of enzyme cleavage, the correlation with ATm values,
which are associated with stabilization of the DNA helix, suggest
that RED1oo values are directly related to DNA-binding affinity.
There is an identical rank order of experimental RED100, ATm,
and EB60 values for sibiromycin, anthramycin and tomaymycin,
with sibiromycin being the most potent. Furthermore, the relative
differences between tomaymycin and the two most potent
compounds are reflected in all three determined parameters. For
the weaker binding compounds, DC-81, neothramycin and iso-
DC-81, the ATm and EB60 values are unable to distinguish
between their relative binding affinities. However, a rank order
is obtained from the relative RED0oo values, suggesting that this
assay method provides greater sensitivity to differences in DNA
binding. Interestingly, the rank order of PBDs based on their
REDIoo values reflects the trend of IC50 values across two cell
lines (L1210 and PC6), except that the rank order of anthramycin
and tomaymycin is reversed in each line.
The DNA-binding data provided by this assay highlight a
number of features of interest concerning structure-activity
relationships (SARs) for the PBDs. First, the least cytotoxic
molecules, DC-81, neothramycin and iso-DC-81, with the lowest
relative DNA-binding affinities, all possess imine functionalities
at the N0O-C1 1 position. Furthermore, these three compounds
it has been previously shown that neothramycin is more
electrophilic at Cll than compounds such as anthramycin or
tomaymycin that contain carbinolamine methyl ether functions
at N10-Cll (14).
The three most potent compounds have in common an
sp2-hybridized C2 carbon (Figure 1), although the unsaturation
is endocyclic in anthramycin and sibiromycin, but exocyclic in
tomaymycin. Based on the RED1OO, ATm and EB60 data for
anthramycin and sibiromycin, endocyclic unsaturation appears
to be significantly more favourable for DNA binding. This may
relate to the more planar profile of molecules with C2-C3
unsaturation, allowing them to conform more easily to the shape
of the minor groove (2,15). Finally, sibiromycin is the only PBD
examined to possess a sugar moiety, and is the most potent of
the group of compounds tested, suggesting that secondary
functionalisation also plays a role in determining relative DNA-
binding affinity.
The experiment with SspI was included to help develop an
understanding of the mechanism of the RED0oo assay at the
molecular level. At present there is little information available
regarding the mechanism of action of BamHI, although some
work has been carried out on other restiction endonucleases such
as EcoRV (16,17). There are two possible mechanisms to explain
the inhibition of BamHI by the PBDs: (i) direct steric inhibition
ofenzyme recognition and/or binding at the enzyme recognition
sequence due to PBD binding, and (ii) indirect interference with
enzyme-mediated processes due to PBD-induced stiffening of the
DNA helix (or other conformational changes) upon binding. If
the latter process is operative, then binding of a PBD ligand at
a location adjacent to the enzyme recognition site might be
expected to inhibit DNA cleavage to some extent. The fact that
SspI is not significantly inhibited by PBDs at similar
concentrations to BamHI in the RED1oo assay lends support to
the first mechanism, involving direct, competitive inhibition.
In summary, the REDIoo assay is a sensitive and apparently
biologically relevant method to determine the relative DNA-
binding affinities of PBDs. This assay is of potential value in
future SAR studies of both naturally-occurring and synthetic
compounds in this family, and should be helpful in studies of
the mechanism of action of DNA-modifying PBDs at the
molecular level.
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